1. Home
  2. OPT

OPT

Opthea Limited

Logo Opthea Limited

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Founded: N/A Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 323.9M IPO Year: 2020
Target Price: $17.67 AVG Volume (30 days): 23.0K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.65 EPS Growth: N/A
52 Week Low/High: $1.60 - $4.42 Next Earning Date: 02-28-2024
Revenue: $385,275 Revenue Growth: 93.60%
Revenue Growth (this year): -61.02% Revenue Growth (next year): N/A

Share on Social Networks: